Background: Whether the diagnosis and treatment of coronavirus disease 2019 (COVID-19) affect the clinical course of patients with hematologic malignancies has been of interest during the COVID-19 pandemic.
Methods: We describe a 47-year-old female who was concurrently diagnosed with COVID-19 and acute myeloid leukemia (AML).
Results: She developed COVID-19 pneumonia which required treatment with remdesivir and dexamethasone, and induction therapy for t-AML was delayed. After her COVID-19 was resolved and isolation ended, follow-up bone marrow examination showed decreased leukemic burden.
Conclusions: This case describes possible effects of COVID-19 treatment on the clinical course of patients with AML from a laboratory perspective.